Drug Safety & Metabolism, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Pepparedsleden 1, Mölndal 431 83, Sweden.
Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Cambridge Science Park, Milton Road, Cambridge CB4 0WG, United Kingdom.
Mol Pharm. 2017 Dec 4;14(12):4346-4352. doi: 10.1021/acs.molpharmaceut.7b00388. Epub 2017 Nov 8.
The drug-induced accumulation of phospholipids in lysosomes of various tissues is predominantly observed in regular repeat dose studies, often after prolonged exposure, and further investigated in mechanistic studies prior to candidate nomination. The finding can cause delays in the discovery process inflicting high costs to the affected projects. This article presents an in vitro imaging-based method for early detection of phospholipidosis liability and a hybrid approach for early detection and risk mitigation of phospolipidosis utilizing the in vitro readout with in silico model prediction. A set of reference compounds with phospolipidosis annotation was used as an external validation set yielding accuracies between 77.6% and 85.3% for various in vitro and in silico models, respectively. By means of a small set of chemically diverse known drugs with in vivo phospholipidosis annotation, the advantages of combining different prediction methods to reach an overall improved phospholipidosis prediction will be discussed.
药物诱导的各种组织溶酶体中磷脂的蓄积主要在常规重复剂量研究中观察到,通常在长期暴露后,并在候选物提名前在机制研究中进一步研究。这一发现可能导致发现过程延迟,给受影响的项目造成高昂的成本。本文提出了一种基于体外成像的方法,用于早期检测磷脂蓄积的风险,并提出了一种利用体外读出与计算模型预测相结合的早期检测和降低磷脂蓄积风险的混合方法。一组具有磷脂蓄积注释的参考化合物被用作外部验证集,为各种体外和计算模型分别产生了 77.6%和 85.3%的准确率。通过一组具有体内磷脂蓄积注释的化学多样性较小的已知药物,将讨论结合不同预测方法以达到整体改善磷脂蓄积预测的优势。